Status:
UNKNOWN
Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI
Lead Sponsor:
Shenyang Northern Hospital
Conditions:
AMI
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Acute myocardial infarction (AMI) is one of the leading causes of death around the world, with the potential for substantial morbidity and mortality. The increasing evidence indicates that exercise tr...
Eligibility Criteria
Inclusion
- Acute myocardial infarction undergoing primary percutaneous coronary intervention;
- Aged 18 years or over and under 80 years;
- 35% \< LVEF \< 50% and LV \< 65mm;
- With informed consents
Exclusion
- Severe symptomatic congestive heart failure (KILLIP cardiac function class III-IV);
- Malignant arrhythmias (ventricular fibrillation, ventricular tachycardia, frequent multiple source ventricular premature);
- Uncontrolled hypertension (systolic blood pressure greater than 160mmhg, diastolic blood pressure greater than 100mmhg);
- Life-threatening diseases with limited life expectancy \<6 months;
- Inability or difficulty to exercise;
- Participation in other clinical trials
Key Trial Info
Start Date :
November 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 11 2023
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT05201274
Start Date
November 11 2021
End Date
February 11 2023
Last Update
January 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Shenyang Military Region
Shenyang, Liaoning, China, 110016